GLP1R and thyroid cancer: Similar to the main analysis, no significant associations between GLP1 receptor agonists versus DPP4 inhibitors and risk of thyroid cancer were observed in additional analyses which used an alternative modified intention-to-treat definition for drug use; included additional adjustment for calendar year; included calendar year in the propensity score; applied calendar time specific propensity scores; and excluded patients with any previous cancer at any time before cohort entry.